Retail News Breaks Archives
London Drugs stores to pilot skin cholesterol test
August 14th, 2012
WINNIPEG, Manitoba – London Drugs plans to pilot a noninvasive skin cholesterol test from Miraculins Inc. this fall.
The medical diagnostic company said Monday that its PreVu Non-Invasive Skin Cholesterol Point of Care (POC) Test, which gauges the risk of coronary artery disease (CAD), is slated to begin its retail pharmacy launch in October at up to 10 London Drugs stores in Vancouver, British Columbia, and the surrounding Lower Mainland area.
Measuring skin cholesterol, a biomarker for coronary artery disease, the painless PreVu POC test involves no blood draw, needles or overnight fasting. It's done on the palm of the hand in less than 5 minutes.
London Drugs will have the option to expand the PreVu POC Test to all 74 of its drug stores as an ongoing service after the completion of the pilot program. According to Miraculins, the expected rollout of PreVu to all London Drugs stores, which likely would start in early 2013, would give the drug chain a period of exclusivity for the test in its western Canada market. The retailer has stores in British Columbia, Alberta, Manitoba and Saskatchewan.
"We have a longstanding tradition of bringing new, innovative and meaningful technologies to our customers, and we are most impressed with the science behind the PreVu POC Test," John Tse, vice president of pharmacy for Richmond, B.C.-based London Drugs, said in a statement. "We believe our customers will benefit from experiencing this convenient, rapid and noninvasive skin cholesterol test and that it can serve to help them begin to gain greater understanding and management of the risk factors they may unknowingly be living with for CAD."
The PreVu POC Test measures skin cholesterol, which Miraculins said is a key biomarker in assessing risk of coronary artery disease. The painless, in vitro diagnostic test — which involves no blood draw or needles and no overnight fasting — is conducted on the palm of the hand in less than 5 minutes. The results are available immediately, which Miraculins noted facilitates point-of-care consultation and discussion with patients about the next steps they can take to address their condition.
PreVu doesn't diagnose the presence or absence of CAD but helps identify patients who may be at higher, hidden risk for the disease, the company said.
"This pilot program is a very significant milestone for PreVu in Canada, as well as a major step forward in the commercialization of the technology worldwide," stated Paul Moreau, vice president of sales and marketing at Miraculins. "We are very pleased that London Drugs, a highly respected retail brand in the health care services sector, wants to make the PreVu POC Test available to its customers to help them better understand their risk of coronary artery disease. With over 70,000 heart attacks in Canada each year, resulting in over 16,000 deaths, this pilot program represents an important development toward realizing better heart health for all Canadians at risk."
The pilot will incorporate the PreVu POC Test into special CAD risk assessment clinics that will be conducted in the London Drugs pharmacies and supported by Pear Healthcare Solutions, a Toronto-based provider of health screening and education services to pharmacy retailers in Canada. Pear Healthcare is the exclusive distributor of the test to that market segment.
"We are very pleased to be working with London Drugs on this pilot program to better serve the health needs of its customers and to provide the organization with a competitive distinction in the marketplace by introducing tailored CAD risk assessment programming into its stores featuring the PreVu POC Test," commented Mark Doyle, vice president of sales and marketing for Pear Healthcare Solutions.